Fig. 3From: Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α, sunitinib, axitinib, and nivolumab therapies: a case reportTime series showing adverse events for treatment with dosage changes of axitinibBack to article page